Show simple item record

2021-05-18Zeitschriftenartikel DOI: 10.3390/v13050932
Aptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies
dc.contributor.authorWeisshoff, Hardy
dc.contributor.authorHaberland, Annekathrin
dc.contributor.authorKrylova, Oxana
dc.contributor.authorNikolenko, Heike
dc.contributor.authorGöttel, Peter
dc.contributor.authorDallmann, Andre
dc.contributor.authorMüller, Johannes
dc.date.accessioned2021-08-12T11:05:59Z
dc.date.available2021-08-12T11:05:59Z
dc.date.issued2021-05-18none
dc.date.updated2021-06-11T14:14:41Z
dc.identifier.urihttp://edoc.hu-berlin.de/18452/23839
dc.description.abstractCOVID-19 is a pandemic respiratory disease that is caused by the highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Anti-SARS-CoV-2 antibodies are essential weapons that a patient with COVID-19 has to combat the disease. When now repurposing a drug, namely an aptamer that interacts with SARS-CoV-2 proteins for COVID-19 treatment (BC 007), which is, however, a neutralizer of pathogenic autoantibodies in its original indication, the possibility of also binding and neutralizing anti-SARS-CoV-2 antibodies must be considered. Here, the highly specific virus-neutralizing antibodies have to be distinguished from the ones that also show cross-reactivity to tissues. The last-mentioned could be the origin of the widely reported SARS-CoV-2-induced autoimmunity, which should also become a target of therapy. We, therefore, used enzyme-linked immunosorbent assay (ELISA) technology to assess the binding of well-characterized publicly accessible anti-SARS-CoV-2 antibodies (CV07-209 and CV07-270) with BC 007. Nuclear magnetic resonance spectroscopy, isothermal calorimetric titration, and circular dichroism spectroscopy were additionally used to test the binding of BC 007 to DNA-binding sequence segments of these antibodies. BC 007 did not bind to the highly specific neutralizing anti-SARS-CoV-2 antibody but did bind to the less specific one. This, however, was a lot less compared to an autoantibody of its original indication (14.2%, range 11.0–21.5%). It was also interesting to see that the less-specific anti-SARS-CoV-2 antibody also showed a high background signal in the ELISA (binding on NeutrAvidin-coated or activated but noncoated plastic plate). These initial experiments suggest that the risk of binding and neutralizing highly specific anti-SARS CoV-2 antibodies by BC 007 should be low.eng
dc.description.sponsorshipTransfer-Bonuns
dc.language.isoengnone
dc.publisherHumboldt-Universität zu Berlin
dc.rights(CC BY 4.0) Attribution 4.0 Internationalger
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectaptamereng
dc.subjectautoantibodyeng
dc.subjectBC 007eng
dc.subjectCOVID-19eng
dc.subjectre-purposingeng
dc.subjectSARS-CoV-2 antibodyeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleAptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodiesnone
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:11-110-18452/23839-4
dc.identifier.doi10.3390/v13050932none
dc.identifier.doihttp://dx.doi.org/10.18452/23223
dc.type.versionpublishedVersionnone
local.edoc.container-titleVirusesnone
local.edoc.pages10none
local.edoc.type-nameZeitschriftenartikel
local.edoc.institutionMathematisch-Naturwissenschaftliche Fakultätnone
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-publisher-nameMDPInone
local.edoc.container-publisher-placeBaselnone
local.edoc.container-volume13none
local.edoc.container-issue5none
dc.description.versionPeer Reviewednone
local.edoc.container-articlenumber932none
dc.identifier.eissn1999-4915
local.edoc.affiliationHaberland, Annekathrin; Berlin Cures GmbH, Robert-Rössle-Str. 10 Blg. D79, 13125 Berlin, Germanynone
local.edoc.affiliationKrylova, Oxana; Leibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP), Robert-Rössle-Str. 10, 13125 Berlin, Germanynone
local.edoc.affiliationNikolenko, Heike; Leibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP), Robert-Rössle-Str. 10, 13125 Berlin, Germanynone
local.edoc.affiliationGöttel, Peter; Berlin Cures GmbH, Knesebeckstr. 59-61, 10719 Berlin, Germanynone
local.edoc.affiliationDallmann, Andre; Department of Chemistry, NMR Facility, Humboldt University of Berlin, Brook-Taylor-Straße 2, 12489 Berlin, Germanynone
local.edoc.affiliationMüller, Johannes; Berlin Cures GmbH, Knesebeckstr. 59-61, 10719 Berlin, Germanynone
local.edoc.affiliationWeisshoff, Hardy; Department of Chemistry, NMR Facility, Humboldt University of Berlin, Brook-Taylor-Straße 2, 12489 Berlin, Germanynone

Show simple item record